Drugs / Narlumosbart
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06738160 | Feb 2025 → Jan 2027 expected | non-small cell lung carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06314698 | Apr → Dec 2024 overdue | disease of bone structure, plasma cell myeloma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05813665 | Apr 2023 → Jun 2028 expected | bone giant cell tumor | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Narlumosbart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05813665 ↗ |
| Action | Inhibit | “Narlumosbart is a recombinant, fully human, anti-receptor activator of nuclear factor kappa-Β ligand (RANKL) IgG4 monoclonal antibody.” NCT06314698 ↗ |
| Modality | Monoclonal antibody | “Narlumosbart is a recombinant, fully human, anti-receptor activator of nuclear factor kappa-Β ligand (RANKL) IgG4 monoclonal antibody.” NCT06314698 ↗ |
| Route | Subcutaneous | “Administered by subcutaneous injection once every 4 weeks.” NCT06314698 ↗ |
| Target | TNFSF11 | “Narlumosbart is a recombinant, fully human, anti-receptor activator of nuclear factor kappa-Β ligand (RANKL) IgG4 monoclonal antibody.” NCT06314698 ↗ |